The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Libtayo (cemiplimab) plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone, according to late-breaking data from exploratory analyses at World Conference on Lung Cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Trodelvy reduces risk of disease progression or death by 38% vs. chemo as first-line therapy in metastatic TNBC

Data from the phase III ASCENT-03 study demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival for Trodelvy (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account